

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
19 April 2001 (19.04.2001)

PCT


(10) International Publication Number  
**WO 01/27209 A1**

- (51) International Patent Classification<sup>7</sup>: C09D 157/04, B05D 5/06, A61L 29/04 // (C09D 157/04, 157:00) (74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).
- (21) International Application Number: PCT/GB00/03985 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 16 October 2000 (16.10.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 9924502.9 15 October 1999 (15.10.1999) GB (84) Designated States (*regional*): ARIPO patent (GH, GM, KE; LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): BIO-COMPATIBLES LIMITED [GB/GB]; Chapman House, Farnham Business Park, Weydon Lane, Farnham, Surrey GU9 8QL (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): DAVIES, Martyn, Christopher [GB/GB]; School of Pharmaceutical Sciences, University of Nottingham, Nottingham NG7 2RD (GB). CLARKE, Stuart [GB/GB]; 33 Birchwood Drive, Skegby, Sutton-in-Ashfield, Nottinghamshire NG17 3EY (GB). LEWIS, Andrew, Lennard [GB/GB]; Biocompatibles Limited, Chapman House, Farnham Business Park, Weydon Lane, Farnham, Surrey GU9 8QL (GB).

**Published:**

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/27209 A1

(54) Title: ZWITTERIONIC POLYMER BLEND MATERIALS

(57) Abstract: A polymer blend for use in a biomedical application comprising: (A) a polymer A, bearing zwitterionic pendant groups; and (B) a hydrophobic addition polymer B, selected from the group consisting silyl(alk)acrylates, alkyl(alk)acrylamides, dialkyl(alk)acrylamides, and alkyl(alk)acrylate polymers, wherein the structure of the blend exhibits phase separation forming a micro-phase segregated structure at a surface. Articles, methods of production and liquid blend compositions are also disclosed. Preferably A is a copolymer of 15 to 30 mole % 2-methacryloyloxyethyl-2'-trimethylammonium ethyl phosphate inner salt and 85 to 70 mole % of a C<sub>6-18</sub> alkyl methacrylate, and B is a homopolymer of a C<sub>4-18</sub> alkyl(meth)acrylate, blended in weight proportions of 1:1 to 1:50.

BEST AVAILABLE COPY

## ZWITTERIONIC POLYMER BLEND MATERIALS

The present invention relates to new polymeric materials, especially suitable for use in biomedical applications, processes for their production, articles formed from such materials and processes for modifying the physical and biological properties of plastic materials.

The medical device industry frequently employs a range of thermoplastic, elastomeric and thermoset materials in medical devices. Many of these polymers were originally developed as engineering materials and their physical and mechanical properties reflect this. Thus a plastic may be employed as a medical device because it possesses physical and mechanical properties suitable for use in a biological environment. However, until recently little attention was paid to the biological properties of these materials. This has resulted in a number of problems with current device materials as a result of adverse biological reactions. Silicone rubbers have been shown to leach toxic silicones when implanted, polyurethanes have been found to degrade by macrophage attack and natural rubbers have caused severe allergic reactions. In addition, PVC, a widely used polymer for medical devices, often contains large quantities of the plasticiser bis-(2-ethylhexyl)phthalate and many studies now show this to be toxic. It is clear, therefore, that many materials possess properties which render them unsuitable for use in biological applications.

Previous attempts to prepare biocompatible materials have mimicked the surface of red blood cells which under normal circumstances exist in the blood without causing any adverse reactions. These cell membranes comprise a phospholipid bilayer with the phosphorylcholine group dominating the external membrane surface. It is believed this outer surface avoids adverse reaction with other biological components. Lipids containing phosphorylcholine groups have been coated on to the surface of device materials and bloodclotting studies showed that they rendered the surface more biocompatible (J A Hayward & D Chapman, Biomaterials, Vol. 5, 135, 1984). These phospholipids have also been used as plasticisers in commercial polymers and have again improved the biocompatibility of the base material (WO-A-87/02684). However these two approaches nevertheless possess disadvantages.

Coating the surface of a finished device has a number of problems, one being the difficulty in coating devices with complex shapes or multiple components; in practice a multi-component device can be impossible to coat. In addition the degree of biocompatibility is dependent on the quality of the coating and how strongly it is bound to the surface; thus defects or scratches in the coating will reduce its effectiveness. The use of a lipid as a plasticiser goes some way to overcome these problems, but the lipid is free to move through the material and can eventually leach out of the system. This can again lead to a reduction in the level of biocompatibility. The lipid also has in addition no mechanical strength and can therefore only be used to soften the base polymer.

In certain circumstances it is desirable to provide a coating in which defined areas provide good biocompatibility whilst other areas invoke an interaction with protein. This has application in devices, graft or other surfaces which require partial assimilation with biological tissue or environments.

We have now devised new blended polymeric materials which seek to overcome these disadvantages. The blends combine the desirable physical and/or mechanical properties of an engineering polymer with the biocompatible properties of a polymer bearing pendant zwitterionic, for example phosphoryl choline, groups.

In our earlier application number WO-A-94/14897 we describe blends of zwitterionic polymers with polymers having desirable physical or mechanical properties. The polymers with which the zwitterionic polymers were blended included polymethylmethacrylate, polyethylene, polystyrene and polyacrylonitrile/polyvinylchloride. Blending processes included forming a common solution of the two polymers in a suitable solvent or solvent mixture. The zwitterionic polymers were usually copolymers of 2-methacryloyloxyethyl-2'-trimethylammonium ethyl phosphate inner salt (MPC) with comonomers, including a variety of hydrophobic monomers, for instance C<sub>4-18</sub>-alkyl methacrylate, and fluoroalkyl methacrylates. The molar proportion of zwitterionic monomer in the polymer was in the range 1:(0.5 to 4). In EP-A-0823458, copolymers of MPC with hydrophobic comonomer are blended with

hydrophobic polymers, usually a segmented polyurethane. The hydrophobic comonomer was selected from styrene and its derivatives, alkyl(meth)acrylates such as linear or branched alkyl methacrylates, vinyl ethers, vinyl chloride, alk-1-ene, alicyclic methacrylates and arylurethane alkyl methacrylates. The zwitterionic monomer may be present in the copolymer in a molar proportion in the range 10 to 70%. All the worked examples used around 30%.

The solid blends are said to show phase separation comprising domains of several hundred  $\mu\text{m}$  or less consisting of the zwitterionic copolymer distributed in continuous hydrophobic polymer. In the examples the main sizes are in the range 1 to 45  $\mu\text{m}$ , as judged under SEM, after exposing the film surface to osmium tetroxide followed by sputtering with carbon.

In EP-A-0079197, polymers with zwitterionic groups which are sulpho- or carboxybetaines are used as antistatic agents or hygroscopic agents in thermoplastic films and fibres for instance for making clothing.

The present invention accordingly provides the use in a biomedical application of a solid blend of:

(A) a polymer A, bearing zwitterionic pendant groups formed from a mixture of ethylenically unsaturated monomers including

i) 5 to 70 mol% zwitterionic monomer of the general formula I:

YBX I



wherein

B is a straight or branched alkylene (alkanediyl), alkyleneoxaalkylene or alkylene oligo-oxaalkylene chain optionally containing one or more fluorine atoms up to and including perfluorinated chains or, if X or Y contains a terminal carbon atom bonded to B, a valence bond;

X is a zwitterionic group; and


Y is an ethylenically unsaturated polymerisable group selected from

30



$\text{CH}_2=\text{C}(\text{R})-\text{CH}_2-\text{O}-$ ,  $\text{CH}_2=\text{C}(\text{R})-\text{CH}_2\text{OC}(\text{O})-$ ,  $\text{CH}_2=\text{C}(\text{R})\text{OC}(\text{O})-$ ,  $\text{CH}_2=\text{C}(\text{R})-\text{O}-$ ,  
 $\text{CH}_2=\text{C}(\text{R})\text{CH}_2\text{OC}(\text{O})\text{N}(\text{R}^1)-$ ,  $\text{R}^2\text{OCCCR}=\text{C}(\text{R})\text{C}(\text{O})-\text{O}-$ ,  $\text{RCH}=\text{CHC}(\text{O})\text{O}-$ ,  
 $\text{RCH}=\text{C}(\text{COOR}^2)\text{CH}_2-\text{C}(\text{O})-\text{O}-$ ,

5



wherein:

R is hydrogen or a  $\text{C}_1$ - $\text{C}_4$  alkyl group;

10  $\text{R}^1$  is hydrogen or a  $\text{C}_1$ - $\text{C}_4$  alkyl group or  $\text{R}^1$  is  $-\text{B}-\text{X}$  where B and X are as defined above; and

$\text{R}^2$  is hydrogen or a  $\text{C}_{1-4}$  alkyl group;

A is  $-\text{O}-$  or  $-\text{NR}^1-$ ;

K is a group  $-(\text{CH}_2)_p\text{OC}(\text{O})-$ ,  $-(\text{CH}_2)_p\text{C}(\text{O})\text{O}-$ ,

15  $-(\text{CH}_2)_p\text{OC}(\text{O})\text{O}-$ ,  $-(\text{CH}_2)_p\text{NR}^3-$ ,  $-(\text{CH}_2)_p\text{NR}^3\text{C}(\text{O})-$ ,  
 $-(\text{CH}_2)_p\text{C}(\text{O})\text{NR}^3-$ ,  $-(\text{CH}_2)_p\text{NR}^3\text{C}(\text{O})\text{O}-$ ,  $-(\text{CH}_2)_p\text{OC}(\text{O})\text{NR}^3-$ ,  
 $-(\text{CH}_2)_p\text{NR}^3\text{C}(\text{O})\text{NR}^3-$  (in which the groups  $\text{R}^3$  are the same or different),  
 $-(\text{CH}_2)_p\text{O}-$ ,  $-(\text{CH}_2)_p\text{SO}_3-$ , or, optionally in combination with B, a valence bond  
 p is from 1 to 12; and



20  $\text{R}^3$  is hydrogen or a  $\text{C}_1$ - $\text{C}_4$  alkyl group; and

ii) 50 to 90 mol% of a comonomer having the general formula II




wherein  $\text{Y}^1$  is selected from

25



30  $\text{CH}_2=\text{C}(\text{R}^5)-\text{CH}_2-\text{O}-$ ,  $\text{CH}_2=\text{C}(\text{R}^5)-\text{CH}_2\text{OC}(\text{O})-$ ,  $\text{CH}_2=\text{C}(\text{R}^5)\text{OC}(\text{O})-$ ,  $\text{CH}_2=\text{C}(\text{R}^5)-\text{O}-$ ,  
 $\text{CH}_2=\text{C}(\text{R}^5)\text{CH}_2\text{OC}(\text{O})\text{N}(\text{R}^6)-$ ,  $\text{R}^7\text{OCCCR}^5=\text{C}(\text{R}^5)\text{C}(\text{O})-\text{O}-$ ,  $\text{R}^5\text{CH}=\text{CHC}(\text{O})\text{O}-$ ,  
 $\text{R}^5\text{CH}=\text{C}(\text{COOR}^7)\text{CH}_2-\text{C}(\text{O})-\text{O}-$ ,



5 wherein:

$R^5$  is hydrogen or a  $C_1$ - $C_4$  alkyl group;

$R^6$  is hydrogen or a  $C_1$ - $C_4$  alkyl group or  $R^6$  is  $R^4$ ;

$R^7$  is hydrogen or a  $C_{1-4}$  alkyl group;

$A^1$  is -O- or - $NR^6$ -; and

10  $K^1$  is a group  $-(CH_2)_qOC(O)-$ ,  $-(CH_2)_qC(O)O-$ ,  
 $-(CH_2)_qOC(O)O-$ ,  $-(CH_2)_qNR^8-$ ,  $-(CH_2)_qNR^8C(O)-$ ,  
 $-(CH_2)_qC(O)NR^8-$ ,  $-(CH_2)_qNR^8C(O)O-$ ,  $-(CH_2)_qOC(O)NR^8-$ ,  
 $-(CH_2)_qNR^8C(O)NR^8-$  (in which the groups  $R^8$  are the same or different),  
 $-(CH_2)_qO-$ ,  $-(CH_2)_qSO_3-$ , or a valence bond

15  $q$  is from 1 to 12;

and  $R^8$  is hydrogen or a  $C_1$ - $C_4$  alkyl group;

and  $R^4$  is a straight, branched or cyclic  $C_{6-24}$  alkyl, alkoxyalkyl having a  
total of 6 to 24 carbon atoms or oligoalkoxyalkyl chain  $C_pH_{2p+1}(OC_qH_{2q})_s$  in  
which  $p$  is 3-24,  $s$  is in the range 2 to 50, in the groups  $C_qH_{2q}$  the  $q$ 's are the  
20 same or different, each  $q$  is 2-6 provided that at least half of the  $q$ 's are 3 or  
more when  $p$  is less than 8,  $C_{1-24}$  fluoroalkyl, straight or branched  $C_{6-24}$  alkenyl,  
 $C_{6-24}$  alkynyl,  $C_{6-24}$  aryl,  $C_{6-24}$  aralkyl, or a siloxane group -  
 $(CR^{18a}_2)_{qq}(SiR^{19}_2)(OSiR^{19}_2)_{pp}R^{19}$  in which each group  $R^{18}$  is the same or different  
and is hydrogen or alkyl of 1 to 4 carbon atoms, or aralkyl, each group  $R^{19}$  is  
25 alkyl of 1 to 4 carbon atoms,  $qq$  is from 1 to 6 and  $pp$  is from 0 to 49; and

(B) a hydrophobic addition polymer B, selected from the group  
consisting of silyl(alk)acrylates,  $C_{4-24}$  alkyl(alk)acrylamides, di  $C_{4-18}$   
alkyl(alk)acrylamides, and  $C_{4-24}$  alkyl(alk)acrylate polymers, wherein the  
structure of the blend exhibits phase separation forming a micro-phase  
30 segregated structure at the surface of an article.

There are also provided novel liquid blends of polymer A and polymer B, articles incorporating the solid blends, liquid blending processes and processes for producing the solid blends from the liquid blends.

5     **(A) Polymer bearing zwitterionic pendant groups**

The polymer is a copolymer of a zwitterionic monomer containing a zwitterionic group and a comonomer containing a hydrophobic group, usually an alkyl group. The presence of residues of such comonomers may serve to alter or improve the compatibility of the polymer (A) for the polymer (B) in the  
10     blend of the present invention.

Preferably, such a hydrophobic group is an alkyl or fluoroalkyl group.


In addition to the zwitterionic monomer and comonomer, such copolymers may further comprise residues of a functional comonomer containing a reactive functional group or an ionic group. Reactive groups may  
15     serve to crosslink the copolymer (A) and/or bind the copolymer (A) to the polymer (B) having desirable physical and/or mechanical properties. In addition such reactive groups may provide reactive moieties at the surface of the blend or may serve to bind the copolymer (A) to the surface of an article. Such functional comonomers are present in the monomer mixture in an amount up to  
20     25 mol%, preferably in the range 0.1 to 10 mol%.

In addition, the monomer mixture for forming polymer (A) may further comprise residues of one or more diluent comonomers, for instance in an amount up to 45 mol%, preferably 1 to 25 mol%.

Monomers and comonomers of ethylenically unsaturated monomers  
25     which may be used in the preferred polymers (A) will now be described in more detail.

**A.1. Monomers Containing a Zwitterionic Group**

In the zwitterionic monomer the general formula I, the zwitterionic group  
30     preferably has the general formula III



III

5

in which the moieties  $A^2$  and  $A^3$ , which are the same or different, are -O-, -S-, -NH- or a valence bond, preferably -O-, and  $W^*$  is a group comprising an ammonium, phosphonium or sulphonium cationic group and a group linking the anionic and cationic moieties which is preferably a  $C_{1-12}$ -alkanediyl group,

10

preferably in which  $W^*$  is a group of formula  $-W^1-N^+R^9_3$ ,  $-W^1-P^+R^{10}_3$ ,  $-W^1-S^+R^{10}_2$  or  $-W^1\text{-Het}^+$  in which:

15

$W^1$  is alkanediyl of 1 or more, preferably 2-6 carbon atoms optionally containing one or more ethylenically unsaturated double or triple bonds, disubstituted-aryl (arylene), alkylene arylene, arylene alkylene, or alkylene aryl alkylene, cycloalkanediyl, alkylene cycloalkyl, cycloalkyl alkylene or alkylene cycloalkyl alkylene, which group  $W^1$  optionally contains one or more fluorine substituents and/or one or more functional groups; and

20

either the groups  $R^9$  are the same or different and each is hydrogen or alkyl of 1 to 4 carbon atoms, preferably methyl, or aryl, such as phenyl, or two of the groups  $R^9$  together with the nitrogen atom to which they are attached form an aliphatic heterocyclic ring containing from 5 to 7 atoms, or the three groups  $R^9$  together with the nitrogen atom to which they are attached form a fused ring structure containing from 5 to 7 atoms in each ring, and optionally one or more of the groups  $R^9$  is substituted by a hydrophilic functional group, and

25


the groups  $R^{10}$  are the same or different and each is  $R^9$  or a group  $OR^9$ , where  $R^9$  is as defined above; or

Het is an aromatic nitrogen-, phosphorus- or sulphur-, preferably nitrogen-, containing ring, for example pyridine.

30


Most preferably, the zwitterionic group of the formula III, has the general formula IV:





- 5 where the groups  $\text{R}^{11}$  are the same or different and each is hydrogen or  $\text{C}_{1-4}$  alkyl, and  $m$  is from 1 to 4, in which preferably the groups  $\text{R}^{11}$  are the same preferably methyl.

Alternatively, the zwitterionic group may be a betaine group (ie in which the cation is closer to the backbone), for instance a sulfo-, carboxy- or  
 10 phospho-betaine. A betaine group should have no overall charge and is preferably therefore a carboxy- or sulfo-betaine. If it is a phosphobetaine the phosphate terminal group must be a diester, i.e., be esterified with an alcohol. Such groups may be represented by the general formula V



in which  $\text{A}^4$  is a valence bond, -O-, -S- or -NH-, preferably -O-;


V is a carboxylate, sulphonate or phosphate diester(monovalently charged) anion;

- 20  $\text{R}^{12}$  is a valence bond (together with  $\text{A}^4$ ) or alkanediyl, -C(O)alkylene- or -C(O)NHalkylene preferably alkanediyl, and preferably containing from 1 to 6 carbon atoms in the alkanediyl chain;

the groups  $\text{R}^{13}$  are the same or different and each is hydrogen or alkyl of 1 to 4 carbon atoms or the groups  $\text{R}^{13}$  together with the nitrogen to which  
 25 they are attached form a heterocyclic ring of 5 to 7 atoms; and

$\text{R}^{14}$  is alkyanediyl of 1 to 20, preferably 1 to 10, more preferably 1 to 6 carbon atoms.

One preferred sulphobetaine monomer has the formula VI




where the groups  $R^{15}$  are the same or different and each is hydrogen or  $C_{1-4}$  alkyl and  $s$  is from 2 to 4.

Preferably the groups  $R^{15}$  are the same. It is also preferable that at least one of the groups  $R^{15}$  is methyl, and more preferable that the groups  $R^{15}$  are both methyl.

Preferably  $s$  is 2 or 3, more preferably 3.

Alternatively the zwitterionic group may be an amino acid moiety in which the alpha carbon atom (to which an amine group and the carboxylic acid group are attached) is joined through a linker group to the backbone of the biocompatible polymer. Such groups may be represented by the general formula VII



VII

in which  $A^5$  is a valence bond, -O-, -S- or -NH-, preferably -O-,


$R^{16}$  is a valence bond (optionally together with  $A^5$ ) or alkanediyl, -C(O)alkylene- or -C(O)NHalkylene, preferably alkanediyl and preferably containing from 1 to 6 carbon atoms; and

the groups  $R^{17}$  are the same or different and each is hydrogen or alkyl of 1 to 4 carbon atoms, preferably methyl, or two or three of the groups  $R^{17}$ , together with the nitrogen to which they are attached, form a heterocyclic ring of from 5 to 7 atoms, or the three group  $R^{17}$  together with the nitrogen atom to which they are attached form a fused ring heterocyclic structure containing from 5 to 7 atoms in each ring.

$B$  is preferably  $C_{2-18}$ , more preferably  $C_{2-6}$ , -alkanediyl, branched, or, preferably, straight chain, that is  $(CH_2)_r$ , where  $r$  is 2 to 18, preferably 2 to 6.

Most preferred definitions of  $R^4$  are  $C_{8-16}$ -alkyl, -fluoroalkyl, -alkenyl or -alkynyl.

Functional comonomer may have the general formula VIII



VIII

where

$R^{20}$  is a valence bond or, more preferably, a straight or branched  $C_{2-24}$  alkanediyl, alkyleneoxyalkylene having total of 2 to 24 carbon atoms or alkylene(oligooxyalkylene) group having a total of 2 to 24 carbon atoms and

Q is a functional group selected from cinnamyl, epoxy,  $-CHOHCH_2Hal$  (in which Hal is a halogen atom), methylol, silyl and siloxyl groups containing one or more reactive substituents such as halogen, for example chlorine, or alkoxy, generally containing from 1 to 4 carbon atoms, for example methoxy or ethoxy, hydroxyl, amino, carboxyl, ethylenically acetylenically unsaturated crosslinkable groups, acetoacetoxy, chloroalkylsulphone, succinimido, tosylate, triflate, imidazolecarbonylamino, optionally substituted triazine, cationic and anionic groups and  $Y^2$  is selected from the same group as  $Y^1$ .

Mixtures of functional comonomers having different groups  $-R^{20}-Q$  may be used. In one preferred embodiment the different monomers the groups  $R^{20}$  are the same or different and each represent  $C_{2-6}$ -alkanediyl, and in one of the monomers the group Q is hydroxyl and in the other Q is a reactive silyl group, preferably having the formula  $Si(OR^{22})_3$ , where each group  $R^{22}$  is  $C_{1-4}$ -alkyl, preferably methyl or ethyl and n is 0 or 1.

For comonomers having functional groups, these may provide cross-linkability, reactivity with the polymer B or with substrates or attachment points for ligands such as pharmaceutically active agents, specific binding moieties, or antithrombogenic agents. Comonomers may alternatively include ionic groups, for instance for providing electrostatic attraction with counterionically charged moieties desired to be bonded to the coating. For instance cationic or cationisable monomers may allow loading of the zwitterionic polymer blend by anionically charged mucopolysaccharides such as heparin, which may reduce thrombogenicity of a device having surfaces formed of the solid blend still further.

In monomers of the formula I and in II and III, Y and both  $Y^1$  and  $Y^2$  are preferably  $H_2C=C(R)C(O)A-$  and  $H_2C=C(R^5)C(O)A^1-$ , respectively. R and  $R^5$  are preferably hydrogen or, more preferably, methyl. A and  $A^1$  are preferably the same and are most preferably  $-O-$ .

The ethylenically unsaturated monomers may include diluent monomers, for instance which may be added to adjust the solubility of the polymer in the coating composition from which it is coated, to adjust the hydrophilicity/phobicity, to control the flexibility of the coating, or for other reasons. Such monomers are generally non-ionic. Suitable diluent monomers are alkyl(alk)acrylates, for instance having 1 to 4 carbon atoms in the alkyl group, N-alkyl- or N,N-dialkyl(alk)acrylamides, for instance having 1 to 4 carbon atoms in the or each alkyl group, (alk)acrylamide, hydroxylalkyl(alk)acrylates, for instance having 1 to 6 carbon atoms in the alkyl group, vinyl lactams, such as vinylpyrrolidone, and styrene. Mixtures may be used.

In a particularly preferred embodiment, polymer A is a poly(2-(methacryloyl oxyethyl)-2'-(trimethyl ammonium) ethyl phosphate inner salt-co-n-dodecyl methacrylate copolymer.

Preferably the zwitterionic monomer is used in the monomer mixture in a molar proportion of 5 to 50%, preferably at least 10%, preferably less than 33%, more preferably in the range 15 to 30%. The comonomer II is generally used in molar proportion of at least 50%, preferably at least 67%, more preferably in the range 70 to 85%. Where functional comonomers provide cross-linkability, the level of reactive cross-linkable groups is preferably in the range 0.1 to 25%. Diluent is preferably included in an amount up to 40%, for instance up to 25%.

#### **Preparation of Polymer (A)**

The polymers (A) bearing pendant zwitterionic groups formed from polymerisable ethylenically unsaturated groups may be prepared by conventional radical polymerisation techniques, typically using thermal, photochemical or redox initiation. Where functional comonomers capable of producing crosslinking are present, the polymerisation conditions are set such that crosslinking does not occur during polymerisation. Thus, for example, actinic radiation would not be used to prepare a polymer containing a monomer which can form crosslinks by exposure to actinic radiation.

For thermal polymerisation a temperature from 40 to 100°C, typically 50 to 80°C is used. For photochemical polymerisation actinic radiation such as

gamma, U.V., visible, or microwave radiation may be used. Typically U.V. radiation of wavelength 200 to 400 nm is used.

The polymerisation is generally performed in a liquid reaction medium, which is for instance a solution or dispersion using a non-polymerisable solvent in which the monomers and preferably also the polymer is soluble, for example  
5 acetonitrile, dimethyl formamide, chloroform, dichloromethane, ethyl acetate, dimethyl sulphoxide, dioxan, benzene, toluene, tetrahydrofuran, or where the polymer does not contain groups which react with protic solvents, water or an alkanol containing from 1 to 4 carbon atoms, e.g. methanol, ethanol or propan-  
10 2-ol. Alternatively, a mixture of any of the above solvents may be used.

The polymerisation is carried out in the presence of one or more free radical generators, usually peroxides or azo initiators, such as benzoyl peroxide, 2,2'-azo-bis(2-methylpropionitrile) or benzoin methyl ether. Other polymerisation initiators which may be used are disclosed in "Polymer  
15 Handbook", 3rd edition, Ed. J. Brandrup and E.H. Immergut, Pub. Wiley-Interscience, New York, 1989. Catalysts may be included.

Generally the polymerisation is performed for 0.1 to 72 hours, preferably 0.5 to 24 hours, and under an inert atmosphere of for example nitrogen or argon.

20 The polymer is generally purified by dialysis, precipitation in a non-solvent (e.g. diethyl ether or acetone) or ultrafiltration. The resulting polymer is generally dried under vacuum, eg. for 5 to 72 hours and has a molecular weight from 10,000 to 10 million, preferably from 20,000 to 1 million.

The polymerisation may be carried out under monomer starved  
25 conditions. The prime determinant of the rate of polymerisation is the rate at which the monomers are added. Thus the rate of consumption of monomers in the polymerisation vessel is substantially the same as the rate of addition of monomers to the vessel. This results in the monomer ratio remaining substantially constant throughout the monomer feed stage, at the end of which  
30 polymerisation is close to completion, for instance at least 90% complete, for instance at least 95% complete as judged by residual monomer. It is, nevertheless, preferred for polymerisation to be continued for a period after

monomer feed is complete. This results in reduction of residual monomer to very low levels. The resultant polymer product can be produced with a molecular weight in the range 50,000 to  $10^6$ , preferably in the range  $(1-5) \times 10^5$  D.

5           The monomer starved process results in production of polymers having very low compositional variation. The zwitterionic monomers and hydrophobic comonomer having different reactivity constants, will normally polymerise at different rates. Furthermore, the monomers tend to react with growing polymer chains having end groups of the same type rather than a different type, thereby  
10           forming blocky copolymers. The polymers of the present invention tend to have a much lower compositions variation on a molecular and sub-molecular scale. Such a feature may be used to tailor polymer (A) to polymer (B) in order to provide a suitable blend according to the present invention.

          The precise proportion and nature of the various comonomers used to  
15           prepare a copolymer comprising residues of a comonomer containing a zwitterionic group and a further comonomer may be adjusted to provide a copolymer which is particularly suitable for blending to a particular polymer (B), in particular to provide a particular copolymer suitable for producing a specific micro-phase segregated structure.

20           In addition the monomer or comonomer composition may comprise further components such as a polymerisation initiator, chain transfer agent, acid, base, surfactant, emulsifier or catalyst of conventional type each in an amount from 0.1% to 5%, typically from 0.2% to 3% and preferably about 0.5%, by weight each relative to the total weight of the monomers.

25

#### **(B) Polymers having desirable physical and/or mechanical properties**

          Preferably, the polymer B is a hydrophobic addition polymer, selected from polymers of alkyl(alk)acrylates most preferably straight or branched  $C_{4-18}$ -alkyl(meth)acrylate, more preferably a homopolymer, such as of n-dodecyl  
30           methacrylate.

### **Blending**

Generally the blends of the present invention will contain from 1 to 90% by weight of polymer (A) containing pendant zwitterionic groups and from 99 to 10% of hydrophobic polymer (B). The precise proportions of the polymers (A) and (B) will depend upon the compatibility of the two polymers for blending and, it may be necessary to test the polymers together for their compatibility. This may be achieved by blending different proportions of the polymers (A) and (B) to obtain a blend with the desired balance of mechanical and physical properties as well as biocompatibility. In particular, the proportions of the two polymers may be adjusted so as to obtain desired impact resistance, tensile strength, flexural modulus, low temperature brittleness, friction co-efficient, film permeability, film tear resistance, film shrinkage, surface and volume resistivity, surface wettability and/or contact angle. Most particularly, the proportions are adjusted to obtain a blend which produces a micro-phase segregated structure upon removal of a solvent from the blend solution or dispersion.

The applicants have found that a zwitterion group-containing copolymer prepared by copolymerization with a comonomer, as hereinbefore described, can give a stable uniform solution when dissolved together with a hydrophobic polymer B, in a single solvent or mixed solvent. Such novel liquid blends form part of the invention. Evaporation of the solvent results in phase separation and the production of micro-phase segregated structure at the surface of an formed or coated article. Domains of several hundred micrometers to as little as a few nanometers can be formed, comprising the zwitterion containing copolymer, the domains being uniformly distributed at the surface of the hydrophobic polymer.

Preferred solvents for forming the liquid blend of the invention include but are not restricted to low boiling point (<100°C) chlorinated solvents. For example, dichlororethane or chloroform. Chloroform is particularly preferred. Other solvents include lower alcohols such as methanol, ethanol, n-propanol, propane-2-ol and solvents such as esters and ethers, particularly ethylacetate and tetrahydrofuran.

The minimum quantity of polymer (A) will depend upon the particular polymer (B), the content of zwitterionic groups in the polymer (A) and the desired use of the blend. Preferably the blend will contain at least 1%, more preferably 10% and still more preferably 30% of polymer (A).

5 In a process of the invention the liquid blend is used to coat or form an article, for instance by shaping the liquid and then removing the solvent by evaporation. In a preferred embodiment a coating of the liquid blend is formed on the surface of a preformed article and the solvent is removed by evaporation to form a coating of solid blend A and B. The polymers of the blend may, after  
10 coating, be bound to the article by hydrogen-bonding interactions, by chemical reaction to provide a covalent bond with the underlying polymer surface or by counterionic attraction between oppositely charged ionic groups on the zwitterionic polymer and on the coated surface. Particularly preferred surfaces to be coated include silicones, polyurethanes, polyalkacrylates, polystyrene,  
15 polycarbonate, and metals (particularly stainless steel).

The hydrophobic domains of the novel solid blend may also be expressed at the surface of a coated article produced by the process of the invention. The overall concept is based on the use of the zwitterionic group expression at the article surface to reduce non-specific adsorption of proteins  
20 and other biological moieties, whilst the hydrophobic domains provide controlled sites of hydrophobicity that may provide anchorage for cells or other proteinaceous deposits to spread, grow or accumulate at these sites. The microdomains are for instance less than 1  $\mu\text{m}$  in diameter, usually less than about 500  $\mu\text{m}$ , often less than 200  $\mu\text{m}$  in diameter.

25 Alternatively, the hydrophobic domains may be destabilized and removed to provide selective exposure of the underlying article surface which may provide anchorage for biological moieties as described above. Such destabilization can be effected in a number of ways, for example, contact with water or other solvents, aqueous or organic may disrupt the hydrophobic  
30 domains. It is believed that polymer B resiles from the surface into the bulk of the coating and polymer A is relatively more exposed upon such contact.



The utility of this invention is primarily in the medical field, for instance for any instrument which requires partial assimilation with biological systems. Such instruments are for instance contact lenses, corneal grafts, vascular grafts, intraocular lenses and other surgical implants or prostheses and  
5 bioseparation apparatus, tubing for use in prostheses, in extra corporeal circuitry. In particular, they are suitable for use as contact lenses, corneal grafts, intra-ocular lenses and other ophthalmic implants.

In addition, the blends of the present invention may further comprise conventional additives used in polymeric materials such as plasticisers, fillers,  
10 colourants, UV absorbers, anti-oxidants and/or preservatives, such as biocides, which may be included in conventional amounts so as to be compatible with the polymers present in the blend.

In the figures:

Figure 1 shows comparison of theoretically calculated and  
15 experimentally derived surface coverage of PLMA, showing the preferential surface expression of MPC:LMA (1:6) as described in Example 1.

Figure 2 shows phase segregation in MPC-LM<sub>6</sub>:poly(LM) blends of effective formulae (a) MPC-LM<sub>14</sub> (b) MPC-LM<sub>35</sub> (c) MPC-LM<sub>50</sub> (d) MPC-LM<sub>100</sub> as described in Example 1.

20 Figure 3 shows AFM of Poly(n-butyl methacrylate):[MPC:LMA (1:2)] Blends as described in Example 2.

Figure 4 shows AFM of Poly(methyl methacrylate):[MPC:LMA (1:2)] Blends as described in comparative Example 1.

Figure 5 shows SPR Traces of fibrinogen passing over PLMA and  
25 MPC:LMA (1:6), demonstrating the protein-resistant nature of MPC:LMA (1:6) and the non-biocompatibility of PLMA as described in Example 3.

Figure 6 shows surface plasmon resonance studies of protein interaction on various blends as described in Example 3, specifically:

Figure 6a shows a comparison of the increase in  $\theta_{SPR}$  for different  
30 composition PLMA:[MPC:LMA (1:6)] blends exposed to fibrinogen.

Figure 6b shows a comparison of the increase in  $\theta_{\text{SPR}}$  for different composition PBMA:[MPC:LMA (1:2)] blends exposed to human serum albumin (HAS) and fibrinogen (Fib).

Figure 6c shows a comparison of the increase in  $\theta_{\text{SPR}}$  for different composition PMMA:[MPC:LMA (1:2)] blends exposed to human serum albumin (HAS) and fibrinogen (Fib).

The present invention will now be illustrated by the following Examples:-

#### Example 1

10 Preparation for poly(2-(methacryloyloxyethyl)-2'-(trimethyl ammonium) ethyl phosphate inner salt-co-n-dodecyl methacrylate (MPC-co-DM<sub>6</sub> (1:6) blended with poly (dodecylmethacrylate) (Poly DM) matrix.

A 1:1 molar quantity of MPC-co-DM<sub>6</sub> and Poly DM was dissolved in chloroform to produce a 0.5% w/w solution. 130µg of the solution was dropped onto a spinning silvered glass plate. The solvent evaporates to give a polymer coated disc.

AFM analysis with phase imaging of the individual polymers shows an homogeneous, non phase-separated surface for both. However, the same analysis of the blends of the two polymers show that the two are immiscible, surface segregation with nanometre sized domains being formed throughout the range of blends studied. In phase mode, the two different phases are represented as dark and light regions on the image. By use of amplitude-phase-distance curves, a fingerprint of both the dark and light regions can be obtained and compared with that obtained from coatings of the individual polymers. This showed unequivocally that the area represented by the dark regions was due to poly(DM) and the light regions poly(MPC-co-DM). Analogous methods were used to provide blends of MPC-co-DM<sub>14</sub>:PolyDM, MPC-co-DM<sub>35</sub>:PolyDM, MPC-co-DM<sub>50</sub>:PolyDM and MPC-co-DM<sub>100</sub>:PolyDM the results of which are shown in Figure 2. These show phase segregation in MPC-co-DM:PolyDM blends of effective formula (a) MPC-co-DM<sub>14</sub>, (b) MPC-co-DM<sub>35</sub>, (c) MPC-co-DM<sub>50</sub> and (d) MPC-co-DM<sub>100</sub>.

Bearing analysis on the images allows a calculation of the relative area covered by both light and dark regions. When these values for the various blends are plotted against that theoretically expected for a mixture of the two polymers (Figure 1), it becomes evident that the poly(MPC-coDM<sub>6</sub>) is being preferentially expressed at the surface. Hence only a small amount of poly(MPC-coDM<sub>6</sub>) is needed to produce a relatively PC-enriched surface.

### Example 2

#### Poly(n-butyl methacrylate) (PBMA):[MPC:LMA (1:2)]

If coatings from blends of poly(n-butyl methacrylate) (PBMA) with MPC:LMA (1:2) are made and imaged as described in Example 1, similar surface morphologies are observed. Figure 3 shows a series of AFM topography and phase images for blends of PBMA:[MPC:LMA (1:2)]. In this case, the dark region represents MPC:LMA (1:2), as its presence on the surface can be clearly seen to decrease as the amount of PBMA in the blend increases.

### Comparative Example 1

#### Poly(methyl methacrylate) (PMMA):[MPC:LMA (1:2)]

If coatings from blends of poly(methyl methacrylate) (PMMA) with MPC:LMA (1:2) are made and imaged as described in Example 1, no phase separation can be detected for any of the blends (Figure 4). It is well known that in blend systems, micelles of one polymer can be formed that are able to migrate to interfaces. The energetics that drive the micellisation will be dependent upon the chemical structure of the two polymers being blended together. In Examples 1 and 2, a PC-copolymer that has a long alkyl chain component is being blended with another alkyl methacrylate. In the case of methyl methacrylate, it may be that this shortest of the alkyl chain methacrylates does not promote the micelle formation and hence no preferential surface expression of the copolymer. Instead, an homogeneous mixture of the two polymers results.

### Reference Example 1

#### Surface Plasmon Resonance Investigations of Blend Surfaces

Surface plasmon resonance (SPR) is a technique that can determine *in-situ* the amount of protein interacting with a surface. Figure 5 shows the SPR traces for the plasma protein fibrinogen (0.05 mg/ml) when passed over PLMA and MPC:LMA (1:6). In SPR, protein adsorption is accompanied by an increase in the angle of minimum light reflection (termed  $\theta_{\text{SPR}}$ ). Passing fibrinogen over the PLMA coating caused an increase in  $\theta_{\text{SPR}}$  of  $286 \pm 9$  mDA, whilst the coating of MPC:LMA (1:6) no increase was detected. PLMA is a very hydrophobic polymer due to the  $\text{C}_{12}\text{H}_{25}$  sidechain and the long hydrocarbon backbone. In contrast, MPC:LMA (1:6) is hydrophilic due to the PC headgroup which has been shown to have a strong affinity for water as a result of its zwitterionic structure. It has been hypothesised that the hydrophilicity of a materials surface has a major influence on the amount of protein that will adsorb and hence can explain the behaviour of these two polymers.

### Example 3

Figure 6 shows the SPR traces for protein adsorption to a variety of blends: (a) PLMA:[MPC:LMA (1:6)]; (b) PBMA:[MPC:LMA (1:2)]; (c) PMMA:[MPC:LMA (1:2)]. These traces demonstrate that for ratios below 2.7:1 for PLMA:[MPC:LMA (1:6)] invention and 5:1 for PBMA:[MPC:LMA (1:2)] (invention) & PMMA:[MPC:LMA (1:2)] (comparative), protein does not adsorb to the coating surface. Obviously, more matrix polymer can be tolerated in the blend system based on MPC:LMA (1:2) in which there is more MPC compared to the MPC:LMA (1:6) system. The amount of protein adsorbing in each case is clearly dependent upon the ratio of the blend and ultimately the amount of PC expressed at the surface.

CLAIMS

1. A polymer blend at the surface of an article for use in a biomedical application comprising:

(A) a polymer A, bearing zwitterionic pendant groups; and formed from a mixture of ethylenically unsaturated monomers comprising

5 i) 5 to 70 mole % of a monomer containing a zwitterionic group, of the formula





I

wherein


10 B is a straight or branched alkylene (alkanediyl), alkyleneoxaalkylene or alkylene oligo-oxaalkylene chain optionally containing one or more fluorine atoms up to and including perfluorinated chains or, if X or Y contains a terminal carbon atom bonded to B, a valence bond;

X is a zwitterionic group; and


15 Y is an ethylenically unsaturated polymerisable group selected from



20  $\text{CH}_2=\text{C}(\text{R})-\text{CH}_2-\text{O}-$ ,  $\text{CH}_2=\text{C}(\text{R})-\text{CH}_2\text{OC}(\text{O})-$ ,  $\text{CH}_2=\text{C}(\text{R})\text{OC}(\text{O})-$ ,  $\text{CH}_2=\text{C}(\text{R})-\text{O}-$ ,  
 $\text{CH}_2=\text{C}(\text{R})\text{CH}_2\text{OC}(\text{O})\text{N}(\text{R}^1)-$ ,  $\text{R}^2\text{OCCRC}=\text{CRC}(\text{O})-\text{O}-$ ,  $\text{RCH}=\text{CHC}(\text{O})\text{O}-$ ,  
 $\text{RCH}=\text{C}(\text{COOR}^2)\text{CH}_2-\text{C}(\text{O})-\text{O}-$ ,



and



wherein:

R is hydrogen or a  $\text{C}_1\text{-C}_4$  alkyl group;

30  $\text{R}^1$  is hydrogen or a  $\text{C}_1\text{-C}_4$  alkyl group or  $\text{R}^1$  is  $-\text{B}-\text{X}$  where B and X are as defined above; and

$\text{R}^2$  is hydrogen or a  $\text{C}_{1-4}$  alkyl group;

A is -O- or -NR<sup>1</sup>-;

K is a group -(CH<sub>2</sub>)<sub>p</sub>OC(O)-, -(CH<sub>2</sub>)<sub>p</sub>C(O)O-,

-(CH<sub>2</sub>)<sub>p</sub>OC(O)O-, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>3</sup>-, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>3</sup>C(O)-,

-(CH<sub>2</sub>)<sub>p</sub>C(O)NR<sup>3</sup>-, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>3</sup>C(O)O-, -(CH<sub>2</sub>)<sub>p</sub>OC(O)NR<sup>3</sup>-,

5 -(CH<sub>2</sub>)<sub>p</sub>NR<sup>3</sup>C(O)NR<sup>3</sup>- (in which the groups R<sup>3</sup> are the same or different),

-(CH<sub>2</sub>)<sub>p</sub>O-, -(CH<sub>2</sub>)<sub>p</sub>SO<sub>3</sub> -, or, optionally in combination with B, a valence bond

p is from 1 to 12; and

R<sup>3</sup> is hydrogen or a C<sub>1</sub>-C<sub>4</sub> alkyl group; and

ii) 50 to 95 mol % of a monomer having the general formula II



10

Y<sup>1</sup>R<sup>4</sup>

II.

wherein Y<sup>1</sup> is selected from


15




CH<sub>2</sub>=C(R<sup>5</sup>)-CH<sub>2</sub>-O-, CH<sub>2</sub>=C(R<sup>5</sup>)-CH<sub>2</sub>OC(O)-, CH<sub>2</sub>=C(R<sup>5</sup>)OC(O)-, CH<sub>2</sub>=C(R<sup>5</sup>)-O-,

CH<sub>2</sub>=C(R<sup>5</sup>)CH<sub>2</sub>OC(O)N(R<sup>6</sup>)-, R<sup>7</sup>OOCCH=CR<sup>5</sup>C(O)-O-, R<sup>5</sup>CH=CHC(O)O-,

20 R<sup>5</sup>CH=C(COOR<sup>7</sup>)CH<sub>2</sub>-C(O)-O-,



and



25 wherein:

R<sup>5</sup> is hydrogen or a C<sub>1</sub>-C<sub>4</sub> alkyl group;

R<sup>6</sup> is hydrogen or a C<sub>1</sub>-C<sub>4</sub> alkyl group or R<sup>6</sup> is R<sup>4</sup>;

R<sup>7</sup> is hydrogen or a C<sub>1-4</sub> alkyl group;

A<sup>1</sup> is -O- or -NR<sup>6</sup>-; and

30

K<sup>1</sup> is a group -(CH<sub>2</sub>)<sub>q</sub>OC(O)-, -(CH<sub>2</sub>)<sub>q</sub>C(O)O-,

-(CH<sub>2</sub>)<sub>q</sub>OC(O)O-, -(CH<sub>2</sub>)<sub>q</sub>NR<sup>8</sup>-, -(CH<sub>2</sub>)<sub>q</sub>NR<sup>8</sup>C(O)-,

-(CH<sub>2</sub>)<sub>q</sub>C(O)NR<sup>8</sup>-, -(CH<sub>2</sub>)<sub>q</sub>NR<sup>8</sup>C(O)O-, -(CH<sub>2</sub>)<sub>q</sub>OC(O)NR<sup>8</sup>-,

$-(CH_2)_qNR^8C(O)NR^8-$  (in which the groups  $R^8$  are the same or different),  
 $-(CH_2)_qO-$ ,  $-(CH_2)_qSO_3-$ , or a valence bond


$q$  is from 1 to 12;

and  $R^8$  is hydrogen or a  $C_1$ - $C_4$  alkyl group;

5 and  $R^4$  is selected from the group consisting of a straight, branched and cyclic  $C_{6-24}$  alkyl, alkoxyalkyl having a total of 6 to 24 carbon atoms or oligoalkoxyalkyl chain  $C_pH_{2p+1}(OC_qH_{2q})_s$  in which  $p$  is 3-24,  $s$  is in the range 2 to 50, in the groups  $C_qH_{2q}$  the  $q$ 's are the same or different, each  $q$  is 2-6 provided that at least half of the  $q$ 's are 3 or more when  $p$  is less than 8,  $C_{1-24}$   
 10 fluoroalkyl,  $C_{6-24}$  alkenyl,  $C_{6-24}$  alkynyl,  $C_{6-24}$  aryl,  $C_{9-24}$  aralkyl and siloxane groups  $-(CR^{18a}_2)_{qq}(SiR^{19}_2)(OSiR^{19}_2)_{pp}R^{19}$  in which each group  $R^{18}$  is the same or different and is hydrogen or alkyl of 1 to 4 carbon atoms, or aralkyl, each group  $R^{19}$  is alkyl of 1 to 4 carbon atoms,  $qq$  is from 1 to 6 and  $pp$  is from 0 to 49.

(B) a hydrophobic addition polymer B, selected from the group  
 15 consisting of silyl(alk)acrylates,  $C_{4-24}$  alkyl(alk)acrylamides, di( $C_{4-24}$ )alkyl(alk)acrylamides, and  $C_{4-24}$  alkyl (alk)acrylate polymers, wherein the structure of the blend exhibits phase separation forming a micro-phase segregated structure at said surface.

2. A blend according to claim 1 in which the zwitterionic group has the  
 20 general formula III



25 in which the moieties  $A^2$  and  $A^3$ , which are the same or different, are  $-O-$ ,  $-S-$ ,  $-NH-$  or a valence bond, preferably  $-O-$ , and  $W^+$  is a group comprising an ammonium, phosphonium or sulphonium cationic group and a group linking the anionic and cationic moieties which is preferably a  $C_{1-12}$ -alkanediyl group,

30 preferably in which  $W^+$  is a group of formula  $-W^1-N^+R^9_3$ ,  $-W^1-P^+R^{10}_3$ ,  $-W^1-S^+R^{10}_2$  or  $-W^1-Het^+$  in which:

$W^1$  is alkanediyl of 1 or more, preferably 2-6 carbon atoms optionally containing one or more ethylenically unsaturated double or triple bonds,


disubstituted-aryl (arylene), alkylene arylene, arylene alkylene, or alkylene aryl alkylene, cycloalkanediyl, alkylene cycloalkyl, cycloalkyl alkylene or alkylene cycloalkyl alkylene, which group W<sup>1</sup> optionally contains one or more fluorine substituents and/or one or more functional groups; and

- 5 either the groups R<sup>9</sup> are the same or different and each is hydrogen or alkyl of 1 to 4 carbon atoms, preferably methyl, or aryl, such as phenyl, or two of the groups R<sup>9</sup> together with the nitrogen atom to which they are attached form an aliphatic heterocyclic ring containing from 5 to 7 atoms, or the three groups R<sup>9</sup> together with the nitrogen atom to which they are attached form a  
10 fused ring structure containing from 5 to 7 atoms in each ring, and optionally one or more of the groups R<sup>9</sup> is substituted by a hydrophilic functional group, and

the groups R<sup>10</sup> are the same or different and each is R<sup>9</sup> or a group OR<sup>9</sup>, where R<sup>9</sup> is as defined above; or

- 15 Het is an aromatic nitrogen-, phosphorus- or sulphur-, preferably nitrogen-, containing ring, for example pyridine.

3. A blend according to claim 2 in which the zwitterionic group of formula III, has the general formula IV:



where the groups R<sup>11</sup> are the same or different and each is hydrogen or C<sub>1-4</sub> alkyl, and m is from 1 to 4, in which preferably the groups R<sup>11</sup> are the same  
25 preferably methyl.

4. A blend according to any preceding claim in which group R<sup>4</sup> is a C<sub>8</sub>-C<sub>16</sub> alkyl, alkenyl

or alkynyl group, preferably a C<sub>8</sub>-C<sub>16</sub> alkyl, most preferably a C<sub>12</sub> alkyl group.

5. A blend according to any preceding claim in which the zwitterionic  
30 monomer is used in the monomer mixture in a molar proportion of at least 10%, preferably in the range of 15 to 30%.



6. A blend according to any preceding claim in which polymer A is a poly(2-(methacryloyloxyethyl)-2'-(trimethyl ammonium) ethyl phosphate inner salt-co-n-dodecyl methacrylate copolymer.
7. A blend according to any preceding claim in which polymer B is a  
5 homopolymer of a C<sub>4-18</sub> alkylmethacrylate, preferably dodecylmethacrylate.
8. A blend according to any preceding claim which contains 1 to 90% (by weight) of polymer A and 10 to 99% of polymer B, preferably at least 10% of polymer A.
9. A process for producing a coating of a blend as defined in any preceding  
10 claim comprising the steps of;
- a) dissolving or dispersing polymer A and polymer B in a solvent to form a liquid blend;
  - b) applying the liquid blend to an article or surface to form a coating of liquid thereon;
  - 15 c) substantially removing the solvent from the coating whereby a solid blend having a micro-phase segregated surface structure is formed.
10. A process according to claim 9 in which the solvent is a chlorinated solvent, preferably chloroform.
11. A process for disrupting the surface produced according to claim 9 or  
20 10 by contacting a disrupting solvent to the surface of the article having a coating of solid blend whereby the blend rearranges such that polymer B resiles from the surface and polymer A is exposed at the surface.
12. A process according to claim 11 in which the disrupting solvent is water.
13. An article having a polymer blend according to any of claims 1 to 12 at  
25 its surface.
14. An article according to claim 13, selected from the group consisting of contact lenses, corneal grafts, intra-ocular lenses.
15. A liquid blend comprising a solvent and dissolved or dispersed in the solvent  
30 (A) a polymer A, bearing zwitterionic pendant groups formed from a mixture of ethylenically unsaturated monomers including

i) 5 to 70 mol% zwitterionic monomer of the general formula I:

YBX

I


wherein

B is a straight or branched alkylene (alkanediyl), alkyleneoxaalkylene or  
 5 alkylene oligo-oxaalkylene chain optionally containing one or more fluorine  
 atoms up to and including perfluorinated chains or, if X or Y contains a terminal  
 carbon atom bonded to B, a valence bond;

X is a zwitterionic group; and


Y is an ethylenically unsaturated polymerisable group selected from

10



15  $\text{CH}_2=\text{C}(\text{R})-\text{CH}_2-\text{O}-$ ,  $\text{CH}_2=\text{C}(\text{R})-\text{CH}_2\text{OC}(\text{O})-$ ,  $\text{CH}_2=\text{C}(\text{R})\text{OC}(\text{O})-$ ,  $\text{CH}_2=\text{C}(\text{R})-\text{O}-$ ,  
 $\text{CH}_2=\text{C}(\text{R})\text{CH}_2\text{OC}(\text{O})\text{N}(\text{R}^1)-$ ,  $\text{R}^2\text{OCCCR}=\text{CRC}(\text{O})-\text{O}-$ ,  $\text{RCH}=\text{CHC}(\text{O})\text{O}-$ ,  
 $\text{RCH}=\text{C}(\text{COOR}^2)\text{CH}_2-\text{C}(\text{O})-\text{O}-$ ,

20



wherein:

R is hydrogen or a  $\text{C}_1\text{-C}_4$  alkyl group;

$\text{R}^1$  is hydrogen or a  $\text{C}_1\text{-C}_4$  alkyl group or  $\text{R}^1$  is  $-\text{B-X}$  where B and X are as

25 defined above; and

$\text{R}^2$  is hydrogen or a  $\text{C}_{1-4}$  alkyl group;

A is  $-\text{O}-$  or  $-\text{NR}^1-$ ;

K is a group  $-(\text{CH}_2)_p\text{OC}(\text{O})-$ ,  $-(\text{CH}_2)_p\text{C}(\text{O})\text{O}-$ ,

$-(\text{CH}_2)_p\text{OC}(\text{O})\text{O}-$ ,  $-(\text{CH}_2)_p\text{NR}^3-$ ,  $-(\text{CH}_2)_p\text{NR}^3\text{C}(\text{O})-$ ,

30  $-(\text{CH}_2)_p\text{C}(\text{O})\text{NR}^3-$ ,  $-(\text{CH}_2)_p\text{NR}^3\text{C}(\text{O})\text{O}-$ ,  $-(\text{CH}_2)_p\text{OC}(\text{O})\text{NR}^3-$ ,

$-(CH_2)_pNR^3C(O)NR^3-$  (in which the groups  $R^3$  are the same or different),  
 $-(CH_2)_pO-$ ,  $-(CH_2)_pSO_3-$ , or, optionally in combination with B, a valence bond  
 p is from 1 to 12; and

$R^3$  is hydrogen or a  $C_1$ - $C_4$  alkyl group; and



5 ii) 50 to 90 mol% of a comonomer having the general formula II



II

wherein  $Y^1$  is selected from


10




15

$CH_2=C(R^5)-CH_2-O-$ ,  $CH_2=C(R^5)-CH_2OC(O)-$ ,  $CH_2=C(R^5)OC(O)-$ ,  $CH_2=C(R^5)-O-$ ,  
 $CH_2=C(R^5)CH_2OC(O)N(R^6)-$ ,  $R^7OOCCH(R^5)=CHC(O)-O-$ ,  $R^5CH=CHC(O)O-$ ,  
 $R^5CH=C(COOR^7)CH_2-C(O)-O-$ ,

20



and



wherein:

$R^5$  is hydrogen or a  $C_1$ - $C_4$  alkyl group;

$R^6$  is hydrogen or a  $C_1$ - $C_4$  alkyl group or  $R^6$  is  $R^4$ ;

$R^7$  is hydrogen or a  $C_1$ - $C_4$  alkyl group;

25  $A^1$  is  $-O-$  or  $-NR^6-$ ; and

$K^1$  is a group  $-(CH_2)_qOC(O)-$ ,  $-(CH_2)_qC(O)O-$ ,

$-(CH_2)_qOC(O)O-$ ,  $-(CH_2)_qNR^8-$ ,  $-(CH_2)_qNR^8C(O)-$ ,

$-(CH_2)_qC(O)NR^8-$ ,  $-(CH_2)_qNR^8C(O)O-$ ,  $-(CH_2)_qOC(O)NR^8-$ ,

$-(CH_2)_qNR^8C(O)NR^8-$  (in which the groups  $R^8$  are the same or different),

30  $-(CH_2)_qO-$ ,  $-(CH_2)_qSO_3-$ , or a valence bond

q is from 1 to 12;

and R<sup>8</sup> is hydrogen or a C<sub>1</sub>-C<sub>4</sub> alkyl group;

and R<sup>4</sup> is selected R<sup>4</sup> is preferably a straight, or cyclic or branched C<sub>6-24</sub> alkyl, alkoxyalkyl having a total of 6 to 24 carbon atoms or oligoalkoxyalkyl chain C<sub>1-24</sub> fluoroalkyl straight or branched C<sub>6-24</sub> alkenyl, C<sub>6-24</sub> alkynyl, C<sub>6-24</sub> aryl, C<sub>6-24</sub> aralkyl, or a siloxane group -(CR<sup>18a</sup><sub>2</sub>)<sub>qq</sub>(SiR<sup>19</sup><sub>2</sub>)(OSiR<sup>19</sup><sub>2</sub>)<sub>pp</sub>R<sup>19</sup> in which each group R<sup>18</sup> is the same or different and is hydrogen or alkyl of 1 to 4 carbon atoms, or aralkyl, each group R<sup>19</sup> is alkyl of 1 to 4 carbon atoms, qq is from 1 to 6 and pp is from 0 to 49; and

(B) a hydrophobic addition polymer B, selected from the group consisting of silyl(alk)acrylates, C<sub>4-24</sub> alkyl(alk)acrylamides, di C<sub>4-18</sub> alkyl(alk)acrylamides, and C<sub>4-24</sub> alkyl (alk)acrylate polymers.

16. A composition comprising a blend of polydodecylmethacrylate and poly(2-(methacryloyloxyethyl)-2'-(trimethyl ammonium) ethyl phosphate inner salt-co-n-dodecyl methacrylate copolymer.

17. A composition according to claim 16 in which the ratio of polydodecylmethacrylate and poly(2-(methacryloyloxyethyl)-2'-(trimethyl ammonium) ethyl phosphate inner salt-co-n-dodecyl methacrylate copolymer is in the range 1:1 to 50:1.

18. A composition according to claim 16 or 17 which is a liquid blend comprising at least one solvent.

19. A liquid blend according to claim 15 or 18 in which the solvent is selected from the group consisting of chlorinated alkanes, alcohols, esters, ethers and water.

20. A composition according to any of claims 15, 18 or 19 in which the solvent is selected from chloroform and dichloromethane.

1/5




Figure 1




Figure 2

2/5




Figure 3

3/5




Figure 4

4 / 5




Figure 5



;




Figure 6a




Figure 6b




Figure 6c

# INTERNATIONAL SEARCH REPORT

National Application No.

PCT/GB 00/03985

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 7 C09D157/04 B05D5/06 A61L29/04 //(C09D157/04,157:00)

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C09D B05D A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 14897 A (JONES STEPHEN ALISTER ;STRATFORD PETER WILLIAM (GB); RIMMER STEVEN) 7 July 1994 (1994-07-07) cited in the application claim 17; table 1 ---	1
A	EP 0 823 458 A (JAPAN SCIENCE & TECH CORP ;NOF CORP (JP)) 11 February 1998 (1998-02-11) cited in the application claim 1 -----	1

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

23 January 2001

Date of mailing of the international search report

08/02/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Schueler, D

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/03985

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9414897	A	07-07-1994	AT 178927 T	15-04-1999
			AU 674724 B	09-01-1997
			AU 5711094 A	19-07-1994
			CA 2129905 A	07-07-1994
			DE 69324480 D	20-05-1999
			DE 69324480 T	12-08-1999
			DK 626983 T	25-10-1999
			EP 0626983 A	07-12-1994
			ES 2129620 T	16-06-1999
			JP 7504459 T	18-05-1995
			US 6150432 A	21-11-2000
			US 5712326 A	27-01-1998
<hr/>				
EP 0823458	A	11-02-1998	US 5977257 A	02-11-1999
			JP 9012904 A	14-01-1997
			WO 9634061 A	31-10-1996
<hr/>				

Form PCT/ISA/210 (patent family annex) (July 1992)

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**